Avid Bioservices Inc (CDMO)

[freethemice]

1) betabodies are still too large to get through the blood brain barrier.
2) I don't think so, what matters is that PS is the target.
3) There should be plenty of beta2-GPI around for bavi. I think Thorpe
addressed this question at the NYAS talk last year. A betabody still need two
PS molecules for binding. It might be possible for more of the betabodies to
bind within a given space because they are smaller.
4) This is what I think will make all the difference. This might allow more betabodies
to find PS targets. Perhaps it will also allow the betabodies to have a greater
effect on the repolarization of the tumor microenvironment.
We'll have to see preclinical data to know.